Catalog No.
DHB91601
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
Transforming growth factor beta-1 proprotein, LAP, TGF-beta-1, TGFB1, TGFB
Concentration
1.89 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01137
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
GC-1008, CAS: 948564-73-6
Clone ID
Fresolimumab
[Fresolimumab: A new treatment option for systemic scleroderma on the horizon?], PMID: 26391323
89 Zr-Labeled fresolimumab (human anti-transforming growth factor-β monoclonal antibody), PMID: 22299190
A Functional Genomic Meta-Analysis of Clinical Trials in Systemic Sclerosis: Toward Precision Medicine and Combination Therapy, PMID: 28011145
A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis, PMID: 21368745
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis, PMID: 29270487
Antibody targeting of TGF-β in cancer patients, PMID: 21619535
Antibody-based therapies for idiopathic pulmonary fibrosis, PMID: 32098521
Anti-transforming growth factor-β therapy in patients with myelofibrosis, PMID: 23682558
Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients, PMID: 31296256
Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008), PMID: 25579378
Discovery of Selective Transforming Growth Factor β Type II Receptor Inhibitors as Antifibrosis Agents, PMID: 34055221
Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer, PMID: 29476019
Focal segmental glomerulosclerosis: molecular genetics and targeted therapies, PMID: 26156092
Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients, PMID: 26098215
Gateways to clinical trials, PMID: 20140276
Immunotherapy of systemic sclerosis, PMID: 29985736
Metastasis and the Tumor Microenvironment: A Joint Metastasis Research Society-AACR Conference - Research on Metastasis: part 2, PMID: 21046523
Monoclonal antibodies for renal diseases: current concepts and ongoing treatments, PMID: 26087994
Novel TGF- β inhibitors ready for prime time in onco-immunology, PMID: 28197376
PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models, PMID: 22072706
Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma, PMID: 24618589
Positron Emission Tomography Imaging of Functional Transforming Growth Factor β (TGFβ) Activity and Benefit of TGFβ Inhibition in Irradiated Intracranial Tumors, PMID: 33007434
Recent advances in the treatment of skin involvement in systemic sclerosis, PMID: 29259711
Recent Advances in Treatments of Primary Focal Segmental Glomerulosclerosis in Children, PMID: 27195285
Structures of a pan-specific antagonist antibody complexed to different isoforms of TGFβ reveal structural plasticity of antibody-antigen interactions, PMID: 25209176
Targeted Therapy in Systemic Sclerosis, PMID: 27824545
Targeting TGF-β Signaling in Kidney Fibrosis, PMID: 30150520
TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET, PMID: 26135113
TGFβ-Directed Therapeutics: 2020, PMID: 32835827
Treatment of idiopathic focal segmental glomerulosclerosis: options in the event of resistance to corticosteroids and calcineurin inhibitors, PMID: 23897176
For research use only. Not for human or drug use.
